BLINATUMOMAB

Approval Year

Substance Class	Protein
Protein Type	BISPECIFIC ANTIBODY
Protein Sub Type	SCFV
Sequence Origin	MOUSE
Sequence Type	COMPLETE
Record UNII	4FR53SIF3A
Record Status	`Validated (UNII)`
Record Version

Show entries

Name

Type

Language

BLINATUMOMAB

Official Name

English

AMG103

Code

English

BLINCYTO

Brand Name

English

blinatumomab [INN]

Common Name

English

BLINATUMOMAB [MI]

Common Name

English

Showing 1 to 5 of 16 entries

Previous1 2 3 4Next

Show entries

Classification Tree

Code System

Code

Antineoplastic Biological Agent

NCI_THESAURUS

C129822

Monoclonal Antibody

NCI_THESAURUS

C112889

Monoclonal antibodies

WHO-ATC

L01XC19

Designated

FDA ORPHAN DRUG

203405

Established Pharmacologic Class

NDF-RT

N0000191421

Showing 1 to 5 of 14 entries

Previous1 2 3Next

Show entries

Code System

Code

Type

Description

NDF-RT

N0000191422

PRIMARY

CD19-directed Antibody Interactions [MoA]

MERCK INDEX

m11822

PRIMARY

ChEMBL

CHEMBL1742992

PRIMARY

NCI_THESAURUS

C62528

PRIMARY

DAILYMED

4FR53SIF3A

PRIMARY

Showing 1 to 5 of 18 entries

Previous1 2 3 4Next

Subunit 0

Show entries

Related Record

Type

Details


					IYZ9TI08W3

B-LYMPHOCYTE ANTIGEN CD19

TARGET->LIGAND

Amount:


					ZLW14X2D30

CD3

TARGET -> ACTIVATOR

Amount:

Showing 1 to 2 of 2 entries

Previous1Next

Show entries

Related Record

Type

Details


					4FR53SIF3A

BLINATUMOMAB

ACTIVE MOIETY

Amount:

Showing 1 to 1 of 1 entries

Previous1Next

Name	Property Type	Amount	Parameters
Biological Half-life	PHARMACOKINETIC	2.1 hours (average)	ROUTE OF ADMINISTRATION PHARMACOKINETIC INTRAVENOUS

Molecular Formula	CHEMICAL	ESTIMATED C2367H3574N649O772S19
Volume of Distribution	PHARMACOKINETIC	3.4 LITERS [2.82 to 3.94] (average)	ROUTE OF ADMINISTRATION PHARMACOKINETIC INTRAVENOUS

MOL_WEIGHT:NUMBER(CALCULATED)	CHEMICAL	ESTIMATED 54100 Da (average)